Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Trastuzumab (Herceptin®)

Acknowledgements

Membership of the NBCC* Trastuzumab guideline working group

This guideline was developed by a multidisciplinary working group convened by the National Breast Cancer Centre*

Professor Ian Olver Medical Oncologist (Chair)
Dr Jacquie Chirgwin Medical Oncologist
Dr Anna Nowak Medical Oncologist
Dr Susan Pendlebury Radiation Oncologist
Dr Andrew Spillane Surgeon
Dr Peter Willsher Surgeon
Associate Professor Michael Bilous Pathologist
Professor Patsy Yates Nurse
Associate Professor Ron Tomlins General Practitioner
Ms Veronica Macaulay-Cross Consumer Representative
Ms Rita Marigliani Consumer Representative

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

NBCC* staff

Dr Alison Evans, Ms Ornella Care, Dr Helen Zorbas

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Pharmaceutical Benefits Scheme listing for trastuzumab

As of November 2006. For updates after this date go to http://www.medicareaustralia.gov.au/providers

Herceptin (Trastuzumab) is currently subsidised for the treatment of HER2-positive patients with metastatic breast cancer:

  • in combination with taxanes for patients who have not received chemotherapy for metastatic disease
  • as monotherapy for the treatment of those patients who have received one or more chemotherapy regimen(s) for metastatic disease.

Herceptin (Trastuzumab) is currently subsidised for the treatment of HER2-positive patients with early breast cancer:

  • concurrently with chemotherapy following surgery; restrictions apply, see website for further information.

Development process

Priority topic areas for NBOCC* guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded. The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.

Recommendations for use of Trastuzumab (Herceptin ) for the treatment of HER2-positive breast cancer was prepared and produced by:

National Breast and Ovarian Cancer Centre*
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
Website: www.nbocc.org.au

Cancer Australia 2011
ISBN Print: 978-1-74127-016-7 Online: 978-1-74127-017-4 CIP: 614.5999449

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the National Breast Cancer Centre*. Requests and enquiries concerning reproduction and rights should be addressed to Corporate Communications Manager, National Breast and Ovarian Cancer Centre*.

Recommended citation
National Breast Cancer Centre*. Recommendations for use of Trastuzumab (Herceptin ) for the treatment of HER2-positive breast cancer. National Breast Cancer Centre*, Camperdown, NSW, 1450.

Disclaimer
National Breast and Ovarian Cancer Centre* does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre* develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.

National Breast and Ovarian Cancer Centre* is funded by the Australian Government Department of Health and Ageing.

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Published using CeCC Docbook Manager